Cheryl A Stoddart

Title: Cheryl A. Stoddart: Innovator in CD47 Targeted Therapies

Introduction: Cheryl A. Stoddart, based in Pacifica, California, is a prominent inventor with a significant contribution to the field of biomedical innovations. With a total of five patents to her name, she has focused her research on developing targeted therapies for infectious diseases, specifically through the manipulation of CD47 pathways.

Latest Patents: Among her latest groundbreaking patents, Cheryl Stoddart has developed methods for treating subjects with intracellular pathogen infections. The patented methods involve administering an agent that reduces the binding of CD47 on the infected cell to SIRPα on host phagocytic cells. This innovative approach aims to enhance the phagocytosis of infected cells, paving the way for new therapeutic strategies in combating infections.

Career Highlights: Cheryl has worked with esteemed institutions such as Leland Stanford Junior University and the University of California, contributing to significant advancements in her field. Her dedication to research and development has established her as a leading figure in her area of expertise, focusing on critical health issues.

Collaborations: Throughout her career, Cheryl has collaborated with other distinguished researchers, including Kipp Andrew Weiskopf and Kim J. Hasenkrug. These collaborations have not only enriched her work but also expanded the reach and impact of her innovations in medical therapies.

Conclusion: With her impressive portfolio of patents and collaborations, Cheryl A. Stoddart continues to be an influential innovator in the realm of targeted therapies for infectious diseases. Her research efforts are vital in advancing the understanding and treatment of various infectious conditions, solidifying her position as a key inventor in the biomedical field.